ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR/ARHP Annual Meeting 2016

Abstract Number: 2147

Lack of Pro-Inflammatory Cyto/Chemokines in ANA+ Individuals with Insufficient Criteria for a Diagnosis of Systemic Autoimmune Rheumatic Disease

Waleed Hafiz1, Nan-Hua Chang2, Babak Noamani3, Dennisse Bonilla3, Larissa Lisnevskaia4, Earl Silverman5, Arthur Bookman6, Sindhu R. Johnson7, Carolina Landolt-Marticorena3 and Joan Wither3, 1Rheumatology, University of Toronto, Toronto, ON, Canada, 2Genetics and Development, Krembil Research Institute, University Health Network, Toronto, ON, Canada, 3Krembil Research Institute, University Health Network, Toronto, ON, Canada, 4Lakeridge Health Services, Oshawa, ON, Canada, 5Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, 6Rheumatology, University Health Network, Toronto, ON, Canada, 7Rheumatology, Mount Sinai Hospital and University Health Network, Toronto, ON, Canada

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR/ARHP Annual Meeting 2016

Date of first publication: September 28, 2016

Keywords: ANA, autoimmune diseases and cytokines

Session Information

Date: Tuesday, November 15, 2016

Title: Cytokines, Mediators, Cell-Cell Adhesion, Cell Trafficking and Angiogenesis - Poster II

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Patients with Systemic Autoimmune Rheumatic Disease (SARD) often have a prolonged pre-clinical phase during which they are anti-nuclear antibody (ANA) positive but lack clinical symptoms. It has been proposed that progression from asymptomatic autoimmunity to clinical disease is accompanied by immunologic changes that could be used as predictors of disease development. Our objective was to identify cyto/chemokine abnormalities in ANA+individuals who lack sufficient criteria for a diagnosis of SARD.

Methods: ANA+ individuals who: 1) lacked clinical symptoms of SARD (ANA No Symptoms, ANS); 2) had a least one clinical symptom of SARD (Undifferentiated Connective Tissue Disease, UCTD); or 3) had a recently diagnosed steroid and immunosuppressive naïve SARD were recruited, and compared with ANA– healthy controls (HC). The levels of 30 cyto/chemokines were measured, 29 by Luminex and one (BAFF) by ELISA. Peripheral blood interferon (IFN)-induced and BAFF gene expression was quantified by NanoString. The normalized levels of 5 ubiquitously expressed IFN-induced genes were summed to produce an IFN5 score.

Results: Cyto/chemokines were measured in plasma samples for 145 individuals (21 HC, 37 ANS, 28 UCTD, and 59 early SARD (6 SLE, 25 SjD, 25 SSc, and 3 MCTD/DM)). The plasma levels of four cyto/chemokines, IP-10, eotaxin, BAFF, and TNF-α, were significantly elevated in early SARD patients when compared to HC (Bonferroni corrected p = 0.0001, 0.0006, 0.003, 0.033, respectively). The levels of IP-10, eotaxin, and TNF-α were not significantly elevated in ANS and UCTD individuals as compared to HC. Although there was a trend to elevated serum BAFF levels in UCTD and ANS individuals, this only achieved statistical significance in UCTD patients (p = 0.037 and 0.065, respectively). However, ANS individuals had significant elevations of BAFF RNA in their peripheral blood (p = 0.009). We have previously reported that all ANA+ subgroups (ANS, UCTD and early SARD) have significantly elevated IFN5 scores. The levels of IP-10, serum BAFF, and BAFF RNA were positively correlated with IFN5 scores in ANA+individuals, suggesting that these pro-inflammatory factors are induced by type I IFN.

Conclusion: Although elevated levels of several pro-inflammatory factors are seen in early SARD patients, these factors are not elevated in ANA+ individuals who lack sufficient criteria for a diagnosis of SARD. Thus, elevations of pro-inflammatory factors appear to parallel progression to clinical disease.


Disclosure: W. Hafiz, None; N. H. Chang, None; B. Noamani, None; D. Bonilla, None; L. Lisnevskaia, None; E. Silverman, None; A. Bookman, None; S. R. Johnson, None; C. Landolt-Marticorena, None; J. Wither, None.

To cite this abstract in AMA style:

Hafiz W, Chang NH, Noamani B, Bonilla D, Lisnevskaia L, Silverman E, Bookman A, Johnson SR, Landolt-Marticorena C, Wither J. Lack of Pro-Inflammatory Cyto/Chemokines in ANA+ Individuals with Insufficient Criteria for a Diagnosis of Systemic Autoimmune Rheumatic Disease [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/lack-of-pro-inflammatory-cytochemokines-in-ana-individuals-with-insufficient-criteria-for-a-diagnosis-of-systemic-autoimmune-rheumatic-disease/. Accessed .

ACR Meeting Abstracts - https://acrabstracts.org/abstract/lack-of-pro-inflammatory-cytochemokines-in-ana-individuals-with-insufficient-criteria-for-a-diagnosis-of-systemic-autoimmune-rheumatic-disease/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology